Calcium channels (Ca2+) are proteins, which regulate the influx of calcium into cells. In vascular smooth muscle and cardiac myocytes, calcium influx stimulates muscle contraction and in nodal tissue, it plays an important role in pacemaker currents. Ca+ channel antagonists block the calcium by binding to the L-type calcium channels, thereby resulting in smooth muscle relaxation, decreased myocardial force generation, decreased heart rate, and decreased conduction velocity at the atrioventricular node. Calcium channel antagonists are indicated as antihypertensives, anti-anginal, and anti-arrhythmic agents. Novartis, Sanofi, Incepta Pharma, GSK, CBA Pharma, NVP Healthcare, PDS Biotech, and AbbVie are some of the major players in the Ca+ channel antagonist market. Additionally, Ca+ channel antagonists are in the investigational phase for other indications.
Key Market Developments:
- In Dec 2022, the European Medicines Agency validated the marketing authorization application for Pediatric Praziquantel Consortium’s Arpraziquantel for schistosomiasis in the European Union.
- In January 2023, The Pediatric Praziquantel Consortium announced its intention to start the launch phase of Arpraziquantel for product availability on a not-for-profit basis, initially in sub-Saharan African countries in 2024.
Approved Drug Molecules and Brand Names for Ca2+ channel Antagonists:
- Verapamil
- Diltiazem
- Zonisamide
- Aptiom (Eslicarbazepine)
- Trimetazidine
- Multaq (Dronedarone)
- Telmunivo (s-Amlidioine/ Telmisartan)
- Amlodipine/Atorvastatin
- Nifedipine extended release
- Tekamlo (Aliskiren/Amlodipine)
- Lacidip (Lacidipine)
- Isradipine
- Verapamil modified release
- Amlodipine/Valsartan
- Lercanidipine
- Triplixam (Perindopril arginine/Amlodipine/Indapamide)
- Prialt (Ziconotide)
- Trandolapril/Verapamil
- Olomax (Amlodipine/Olmesartan/Rosuvastatin)
- CBT-1 (Tetrandrine)
- Cilnidipine
- BiDil (Hydralazine/Isosorbide dinitrate)
- Coveram (Perindopril arginine+Amlodipine)
- Nifedipine modified release
- Dukaro (Amlodipine/Fimasartan/Rosuvastatin)
- Telmiduo Plus (Amlodipine/Rosuvastatin/Telmisartan)
- Cilnidipine + Valsartan (AJH801)
- Consensi (Amlodipine/Celecoxib)
- Nivadil (Nilvadipine)
- Rosuampin (YHP1701)
- Verapamil intralesional
Drugs under the Pipeline for Ca2+ channel Antagonists:
- Etripamil (Msp-2017)
- Amlodipine/Ezetimibe/Rosuvastatin/Telmisartan (CKD-348)
- Aceclofenac/Eperisone controlled-release (NVP-1203)
- Arpraziquantel (L-PZQ ODT)
- Celivarone (SSR149744C)
- Exone-R (Amlodipine/Rosuvastatin/Valsartan)
- K201
- Pravitinib (Carboxyamidotriazole orotate)
- Amlodipine/Indapamide/Telmisartan (GMRx2)
- Amlodipine/Rosuvastatin/Telmisartan (YH22189)
- Eperisone controlled-release (DW1030)
- R-Verapamil (CS 02)
- Amlodipine/Rosuvastatin (DP-R212)
- Eperisone controlled-release
- Nimodipine microparticles (EG-1962)
- Ralfinamide (NW-1029)
- ABT-639
- Amlodipine/Atorvastatin
- Amlodipine/Rosuvastatin/Telmisartan (DW-1501)
- Budiodarone (ATI-2042)
- Mesalazine/Nifedipine/Valsartan (IN-C008)
- Aceclofenac/Eperisone (HCP1104)
- Ethosuximide Granules (Adv6770)
Clinical Activity and Developments of Ca2+ Channel Antagonists:
At present, there are 56 drug products in the Ca+ channel antagonists, including more than 20 drug products in the market and the rest of them are in the clinical trial phases.
- In May 2021, Navipharm completed a phase-III trial in back pain in South Korea for Aceclofenac/Eperisone controlled-release.
- In Aug 2022, George Medicines conducted clinical trials in hypertension in Nigeria for Amlodipine/Indapamide/Telmisartan combination.
|
Molecule Name |
Number of Studies |
|
Etripamil (Msp-2017) |
11 |
|
Amlodipine/Ezetimibe/Rosuvastatin/Telmisartan (CKD-348) |
10 |
|
Aceclofenac/Eperisone controlled-release (NVP-1203) |
5 |
|
Arpraziquantel (L-PZQ ODT) |
5 |
|
Celivarone (SSR149744C) |
5 |
|
Exone-R (Amlodipine/Rosuvastatin/Valsartan) |
4 |
|
K201 |
4 |
|
Pravitinib (Carboxyamidotriazole orotate) |
4 |
|
Amlodipine/Indapamide/Telmisartan (GMRx2) |
4 |
|
Amlodipine/Rosuvastatin/Telmisartan (YH22189) |
4 |
|
Eperisone controlled-release (DW1030) |
4 |
|
R-Verapamil (CS 02) |
3 |
|
Amlodipine/Rosuvastatin (DP-R212) |
3 |
|
Eperisone controlled-release |
3 |
|
Nimodipine microparticles (EG-1962) |
3 |
|
Ralfinamide (NW-1029) |
3 |
|
ABT-639 |
2 |
|
Amlodipine/Atorvastatin |
2 |
|
Amlodipine/Rosuvastatin/Telmisartan (DW-1501) |
2 |
|
Budiodarone (ATI-2042) |
2 |
|
Mesalazine/Nifedipine/Valsartan (IN-C008) |
2 |
|
Aceclofenac/Eperisone (HCP1104) |
1 |
|
Ethosuximide Granules (Adv6770) |
1 |
Target Indication Analysis of Ca2+ channel Antagonists
Calcium channel blockers such as amlodipine, benidipine, and cilnidipine (dihydropyridine class) are used for the treatment of angina pectoris, and hypertension. Verapamil is used to reduce myocardial oxygen demand, reverse coronary vasospasm, and also for angina. Verapamil and Diltiazem due to their ability to inhibit the AV node are employed in the management of supraventricular tachyarrhythmias such as atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. Calcium channel antagonists are also used in epilepsy. Some calcium channel blockers are in the clinical trial phases for conditions like hyperlipidemia, Alzheimer’s disease, neuropathic pain, and others.
Regional Analysis of Ca2+ Channel Antagonists
Calcium Channel Antagonists Market
According to the World Health Organization Report 2020, an estimated 17.9 million deaths were attributed to cardiovascular disease (CVD) globally, with the highest mortality rate in Eastern Europe and Central Asia. Globally, it was estimated that in 2020, 244.1 million people were living with ischemic heart disease, being more prevalent in males (141.0 million) and North Africa, the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rate in 2020. The global prevalence rate of stroke in 2020 was 89.1 million with the highest prevalence rates in Southeastern United States and East and Southeast Asia. Based on 2020 data, age-standardized mortality rates attributed to high systolic blood pressure were highest in Central and Southeast Asia, Eastern, and Central Europe, and parts of Africa and the Middle East. The increase in cases of cardiovascular diseases defines the potential for the calcium channel antagonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Verapamil, Diltiazem, Zonisamide, Aptiom (Eslicarbazepine), Trimetazidine, Multaq (Dronedarone), Telmunivo (s-Amlidioine/ Telmisartan), Amlodipine/Atorvastatin are some of the approved Ca2+ channel antagonists.
Novartis, Sanofi, Incepta Pharma, GSK, CBA Pharma, NVP Healthcare, PDS Biotech, and AbbVie are some of the major players in the Ca+ channel antagonist market.
Major indications for Ca2+ channel antagonists are angina, hypertension, atrial fibrillation, atrial flutter and paroxysmal supraventricular tachycardia, and epilepsy.
There are a total of 28 molecules in clinical development for Ca2+ channel antagonists.
- Novartis
- Sanofi
- Incepta Pharma
- GSK
- CBA Pharma
- NVP Healthcare
- PDS Biotech
- AbbVie